anacetrapib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

35 competitors in Randomized

#DrugCompanyPhaseTrials

1

Rayos

RRoxane Laboratories

Phase 3

32

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

13

Yondelis

AApotex Inc.

Phase 3

14

Methylthioninium Chloride

PProvepharm SAS

Phase 3

15

Zytiga

Johnson & Johnson

Phase 2

26

Rituxan

Roche

Phase 2

27

Erleada

Johnson & Johnson

Phase 2

18

Clomid

Ferring

Phase 2

19

Casodex

IIstituto Clinico Humanitas

Phase 2

110

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

1Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Safety and Efficacy3 trials

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Completed·Merck & Co.·Phase 3·NCT01717300·459 enrolled

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Completed·Merck & Co.·Phase 2·NCT00977288·408 enrolled

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Completed·Merck & Co.·Phase 3·NCT01760460·307 enrolled

Familial Hypercholesterolemia2 trials

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Completed·Merck & Co.·Phase 3·NCT01824238·68 enrolled

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Completed·Merck & Co.·Phase 3·NCT01524289·306 enrolled

Dyslipidemia1 trial

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Completed·Merck & Co.·Phase 1·NCT00990808·46 enrolled

Randomized1 trial

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Active, not recruiting·UUniversity of Oxford·Phase 3·NCT01252953·30,449 enrolled

Homozygous Familial Hypercholesterolemia1 trial

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Terminated·Merck & Co.·Phase 3·NCT01841684·2 enrolled

5 more indications

Arterial Stiffness1 trial

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

Completed·—··NCT02931188·103 enrolled

Impaired Renal Function1 trial

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Completed·Merck & Co.·Phase 1·NCT01122667·24 enrolled

Heart Disease1 trial

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Completed·Merck & Co.·Phase 3·NCT00685776·1,623 enrolled

Hepatic Insufficiency1 trial

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Completed·Merck & Co.·Phase 1·NCT01114490·24 enrolled

Hypercholesterolemia1 trial

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Completed·Merck & Co.·Phase 3·NCT01860729·589 enrolled

Details

Drug Info

Related News